It is second installment in partnership based on nicotine research, disease treatment
Jump to full article: Winston-Salem (NC) Journal, 2008-05-06
Author: Richard Craver * Journal Reporter
Intro: Targacept Inc. said yesterday that it has received the second payment from its partnership with GlaxoSmithKline PLC for progress made in its smoking-cessation program.
Targacept, based in Winston-Salem, is developing drugs based on nicotine research that will treat diseases of the central nervous system. The company was spun out from R.J. Reynolds Tobacco Co. in 2000.
The company said that the latest $500,000 payment was awarded for the designation of a lead compound for a smoking-cessation program. Targacept said that these compounds "have the potential to decrease the rewarding effects of nicotine and, as a result, the desire to smoke."
Targacept entered into an agreement with GlaxoSmithKline last July to develop drugs for treating five central-nervous-system disorders.
Jump to full article » |